Abstract
Despite recent advances in the diagnoses and treatment of breast cancer, this disease continues to be a major cause of death. One of the biggest challenges in breast cancer treatment is bone metastasis. Breast cancer cells (BCCs) are capable of migrating to the bone marrow and utilizing the marrow microenvironment to remain quiescent. While exhibiting quiescence in the marrow, BCCs can evade the effects of conventional cancer treatments such as chemotherapy. Therefore, scientists must find a new paradigm to target these quiescent BCCs. The development of potential targets may require a more comprehensive understanding of the marrow microenvironment and its regulators. The preprotachykinin-1 (PPT-I) gene encodes for the tachykinin peptides, which interact with neurokinin (NK) receptors. Studies have correlated this interaction with BCC integration into the bone marrow and breast cancer progression. In this review, we discuss the roles that different factors of the marrow microenvironment play in breast cancer and targets of NK receptors as potential treatment options.
Keywords: Neurokinin receptor, breast cancer, tachykinins, CXCR4, SDF-1α, bone marrow, substance P, preprotachykinin-I
Current Drug Discovery Technologies
Title: Neurokinin Receptors as Potential Targets in Breast Cancer Treatment
Volume: 5 Issue: 1
Author(s): Pranela Rameshwar, Bobby Y. Reddy, Katarzyna A. Trzaska, Raghav G. Murthy and Peter Navarro
Affiliation:
Keywords: Neurokinin receptor, breast cancer, tachykinins, CXCR4, SDF-1α, bone marrow, substance P, preprotachykinin-I
Abstract: Despite recent advances in the diagnoses and treatment of breast cancer, this disease continues to be a major cause of death. One of the biggest challenges in breast cancer treatment is bone metastasis. Breast cancer cells (BCCs) are capable of migrating to the bone marrow and utilizing the marrow microenvironment to remain quiescent. While exhibiting quiescence in the marrow, BCCs can evade the effects of conventional cancer treatments such as chemotherapy. Therefore, scientists must find a new paradigm to target these quiescent BCCs. The development of potential targets may require a more comprehensive understanding of the marrow microenvironment and its regulators. The preprotachykinin-1 (PPT-I) gene encodes for the tachykinin peptides, which interact with neurokinin (NK) receptors. Studies have correlated this interaction with BCC integration into the bone marrow and breast cancer progression. In this review, we discuss the roles that different factors of the marrow microenvironment play in breast cancer and targets of NK receptors as potential treatment options.
Export Options
About this article
Cite this article as:
Rameshwar Pranela, Reddy Y. Bobby, Trzaska A. Katarzyna, Murthy G. Raghav and Navarro Peter, Neurokinin Receptors as Potential Targets in Breast Cancer Treatment, Current Drug Discovery Technologies 2008; 5 (1) . https://dx.doi.org/10.2174/157016308783769450
DOI https://dx.doi.org/10.2174/157016308783769450 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mesenchymal Stem Cells Regulate Cytoskeletal Dynamics and Promote Cancer Cell Invasion Through Low Dose Nitric Oxide
Current Molecular Medicine LPTS: A Novel Tumor Suppressor Gene and a Promising Drug Target for Cancer Intervention
Recent Patents on Anti-Cancer Drug Discovery Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Anthracyclines Still Prove Effective in Anticancer Therapy
Mini-Reviews in Medicinal Chemistry HER2-Mediated Anticancer Drug Delivery: Strategies to Prepare Targeting Ligands Highly Specific for the Receptor
Current Medicinal Chemistry In-Vivo Gene Delivery by Sonoporation: Recent Progress and Prospects
Current Gene Therapy Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Current Pharmaceutical Design Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets The Role of Estrogen and Estrogen Receptors in Chemoresistance
Current Medicinal Chemistry Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Influence of Genetic Factors on the Development of Breast Cancer in the Older Woman
Current Aging Science Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition Pharmacogenetics in Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis and Biological Evaluation of 1,3,4-Thiadiazole Linked Phthalimide Derivatives as Anticancer Agents
Letters in Drug Design & Discovery On the Epistemological Crisis in Genomics
Current Genomics Functional Interplay between RNA-Binding Protein HuR and microRNAs
Current Protein & Peptide Science NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry